Next Article in Journal
Excavatoids E and F: Discovery of Two New Briaranes from the Cultured Octocoral Briareum excavatum
Previous Article in Journal
Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Mar. Drugs 2009, 7(3), 464-471; doi:10.3390/md7030464
Article

Antibacterial Activity of 2-(2’,4’-Dibromophenoxy)-4,6-dibromophenol from Dysidea granulosa

1,* , 2
,
3
,
1
,
2
,
2
 and
2
1 Bioorganic Chemistry, Chemical Oceanography Division, National Institute of Oceanography, Council of Scientific and Industrial Research (CSIR), Dona Paula, 403 004, Goa, India 2 Dept. of Natural Products, Piramal Life Sciences Limited, Nirlon Complex, Goregaon, Mumbai, 400 063, India 3 Dept. of Chemistry, Goa University, Taleigao, 403 206, Goa, India
* Author to whom correspondence should be addressed.
Received: 1 July 2009 / Revised: 1 September 2009 / Accepted: 21 September 2009 / Published: 22 September 2009
View Full-Text   |   Download PDF [144 KB, uploaded 24 February 2015]   |   Browse Figures

Abstract

2-(2’,4’-Dibromophenoxy)-4,6-dibromophenol isolated from the marine sponge Dysidea granulosa (Bergquist) collected off the coast of Lakshadweep islands, Indian Ocean, exhibited potent and broad spectrum in-vitro antibacterial activity, especially against methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive Staphylococcus aureus (MSSA), vancomycin resistant Enterococci (VRE), vancomycin sensitive Enterococci (VSE) and Bacillus spp. Minimal inhibitory concentration (MIC) was evaluated against 57 clinical and standard strains of Gram positive and Gram negative bacteria. The observed MIC range was 0.117-2.5 μg/mL against all the Gram positive bacteria and 0.5-2 μg/mL against Gram negative bacteria. The in-vitro antibacterial activity observed was better than that of the standard antibiotic linezolid, a marketed anti-MRSA drug. The results establish 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol, as a potential lead molecule for anti-MRSA and anti-VRE drug development.
Keywords: Dysidea granulosa; 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol; antibacterial activity; methicillin resistant Staphylococcus aureus; vancomycin resistant enterococci Dysidea granulosa; 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol; antibacterial activity; methicillin resistant Staphylococcus aureus; vancomycin resistant enterococci
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Shridhar, D.M.P.; Mahajan, G.B.; Kamat, V.P.; Naik, C.G.; Parab, R.R.; Thakur, N.R.; Mishra, P.D. Antibacterial Activity of 2-(2’,4’-Dibromophenoxy)-4,6-dibromophenol from Dysidea granulosa. Mar. Drugs 2009, 7, 464-471.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert